SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConvaTec Regulatory News (CTEC)

Share Price Information for ConvaTec (CTEC)

Share Price is delayed by 15 minutes
Get Live Data
202.60    2.60 (1.30%)
Bid:
203.20
Ask:
203.60
Spread: 0.40 (0.197%)
Market Cap: £3.96b
CTEC Live PriceLast checked at - London Stock Exchange

Intraday ConvaTec Share Chart

Executive Committee

3 Apr 2017 15:00

RNS Number : 4097B
ConvaTec Group PLC
03 April 2017
 

 

Executive Committee

 

READING, UNITED KINGDOM (3 April 2017) - It is with deep regret that the Company announces the death of Mike Sgrignari, Executive Vice President, Operations and member of the Executive Committee of ConvaTec Group Plc.

 

Paul Moraviec, Chief Executive Officer, said:

 

"Mike was a hugely talented executive who made a significant and valuable contribution to the development and performance of the Company. On behalf of the management and employees of ConvaTec I wish to publicly express our condolences to Mike's family, colleagues both past and present and friends, for their loss."

 

Since joining ConvaTec in 2015, Mike has built a strong and highly experienced team which will continue to focus on the execution of the Company's Margin Improvement Programme.

Robert Steele, Executive Vice President, Quality, Regulatory & Clinical Affairs will assume interim responsibility for the Operations function.

 

Enquiries

 

ConvaTec

 

Bobby Leach, VP Group Corporate Affairs +44 (0)7770 842226

 

Kirsty Law, Director Investor Relations +44 (0)7470 909582

 

Finsbury

 

Rebecca Fitchett +44 (0)207 2513801

 

 

About ConvaTec

 

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

 

"Nordic Capital" refers to Nordic Capital VII Limited, acting in its capacity as General Partner of Nordic Capital VII Alpha, L.P. and Nordic Capital VII Beta, L.P. together with associated co-investment vehicles and Nordic Capital VI Limited, acting in its capacity as General Partner of Nordic Capital VI Alpha, L.P. and Nordic Capital VI Beta, L.P. together with associated co-investment vehicles.

 

"Avista" is the limited liability companies and limited partnerships managed by Avista Capital Managing Member, LLC with interests in ConvaTec, including Avista Capital Partners LP, Avista Capital Partners II LP and their affiliated funds and co-invest vehicles.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGGDFFDGNZM
Date   Source Headline
13th Sep 202212:08 pmEQSConvatec Group PLC: Scrip Dividend – Calculation Price
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
4th Aug 20227:00 amRNSInterim Results
7th Jul 202211:53 amRNSDirector Declaration
28th Jun 20225:26 pmRNSBlock listing Interim Review
31st May 20222:00 pmRNSTotal Voting Rights
19th May 202210:00 amRNSDirector/PDMR Shareholding
12th May 20224:25 pmRNSResult of AGM
12th May 20227:00 amRNSAGM Trading Update
4th May 20223:31 pmRNSScrip Dividend - Total Issued Shares
3rd May 20227:00 amRNSNotice of Forthcoming Scheduled IR Events
7th Apr 20223:45 pmRNSScrip Dividend – Calculation Price
1st Apr 20224:00 pmRNSHolding(s) in Company
31st Mar 20223:45 pmRNSTotal Voting Rights
30th Mar 202212:00 pmRNSAnnual Report and Accounts 2021 and Notice of AGM
25th Mar 20222:00 pmRNSDirector/PDMR Shareholding
23rd Mar 202211:30 amRNSDirector/PDMR Shareholding
17th Mar 20222:40 pmRNSDirector/PDMR Shareholding
17th Mar 20222:20 pmRNSBoard Change
14th Mar 20227:00 amRNSAcquisition Completion of Triad Life Sciences Inc
8th Mar 20227:00 amRNSAnnual Results
28th Feb 202211:00 amRNSNon-Executive Director Changes
10th Feb 20223:15 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSAcquisition: entry into attractive wound biologics
27th Jan 202211:00 amRNSBoard Committee Changes
20th Dec 20218:45 amRNSBlock Listing Application
16th Dec 20212:00 pmRNSNon-Executive Director appointment
9th Dec 20217:00 amRNSChief Financial Officer succession
1st Nov 20213:35 pmRNSTotal Voting Rights
29th Oct 20217:00 amRNSQ3 Trading Update
18th Oct 20214:30 pmRNSDirector/PDMR Shareholding
1st Oct 20217:00 amRNSPricing of $500M 3.875% Senior Notes due 2029
30th Sep 20211:13 pmRNSConvaTec Announces Offer of $500M Senior Notes
28th Sep 20213:15 pmRNSScrip Dividend - Total Issued Shares
9th Sep 20213:00 pmRNSScrip Dividend - Calculation Price
30th Jul 20213:45 pmRNSDirector/PDMR Shareholding
30th Jul 20217:00 amRNSInterim Results
28th Jun 202112:40 pmRNSDirector Declaration
1st Jun 202111:45 amRNSTotal Voting Rights
17th May 20213:15 pmRNSDirector/PDMR Shareholding
7th May 20212:50 pmRNSResult of AGM
29th Apr 20217:00 amRNSQ1 Trading Update
28th Apr 202112:45 pmRNSScrip Dividend - Total Issued Shares
12th Apr 20213:15 pmRNSScrip Dividend - Calculation Price
22nd Mar 20213:40 pmRNSAnnual Report and Accounts 2020 and Notice of AGM
11th Mar 20213:50 pmRNSDirector/PDMR Shareholding
5th Mar 20217:00 amRNSAnnual Results
22nd Feb 202111:30 amRNSDirector Declaration
21st Dec 202011:00 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.